US 12,344,897 B2
Urinary microbiomic profiling
Trevor Levin, South San Francisco, CA (US); Kevin Phillips, South San Francisco, CA (US); and Christian Rees, South San Francisco, CA (US)
Assigned to Convergent Genomics, Inc., South San Francisco, CA (US)
Filed by Convergent Genomics, Inc., South San Francisco, CA (US)
Filed on Mar. 13, 2024, as Appl. No. 18/603,943.
Application 18/603,943 is a continuation of application No. 17/262,670, previously published as PCT/US2019/043231, filed on Jul. 24, 2019.
Claims priority of provisional application 62/793,693, filed on Jan. 17, 2019.
Claims priority of provisional application 62/703,352, filed on Jul. 25, 2018.
Prior Publication US 2024/0254558 A1, Aug. 1, 2024
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/6806 (2018.01); C12Q 1/6869 (2018.01); C12Q 1/689 (2018.01); G16B 40/30 (2019.01); G16B 50/30 (2019.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/6806 (2013.01); C12Q 1/6869 (2013.01); C12Q 1/689 (2013.01); G16B 40/30 (2019.02); G16B 50/30 (2019.02)] 24 Claims
OG exemplary drawing
 
1. A nucleic acid preservation composition comprising:
(a) an iron chelator,
(b) poly-L-lysine hydrobromide at a mixed molecular weight of 1,000 Da to 5,000 Da, and
(c) one or more agents selected from: (i) a divalent cation chelator that is different from the iron chelator, (ii) D-alpha-tocopherol polyethylene glycol 1000 succinate and (iii) an antimicrobial agent.